TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04027426

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FBT
Description: FBT will receive a family-based, behavioral intervention for childhood obesity, consisting of group meetings once a week for months 1 to 4, twice a month for months 5 to 6, once a month for months 7 to 12, and once every two months for months 13 to 18 (29 sessions). For all meetings, the child and adult caregiver will be weighed and be provided with feedback, homework will be reviewed, and a behavioral lesson will be presented. At the 60-min meetings, the child and adult will attend separate 40 min group meetings, and then for the last 20 min of the meetings they will meet together with an individual therapist to address specific family-issues by developing behavioral action plans. No goals on variety in RED foods will be provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT+Variety
Description: This condition is FBT with a limited variety prescription. The limited variety prescription reduces the number of different RED foods consumed.
Study: NCT06406972

Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.

Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.

Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.

Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.

Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.

Intervention type: OTHER
Intervention: Brief Admission by self-referral (BA)
Description: Through means of an individualised contract access to self-referral to inpatient treatment limited to a maximum of three nights, three times per month.
Study: NCT04154241

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR scan
Description: The PET will be performed with (68Ga)-labeled somatostatin analogue since it was proven to be superior to other NET PET tracers in terms of lesion detection and sensitivity \[11\] \[12\]. The 3 tesla magnet of the MRI should allow acquisition of several contrasts within a reasonable time frame. The protocol will include T1 and T2-weighted images, diffusion-weighted images with multiple b values and apparent diffusion coefficient (ADC) maps.~All images will be analyzed with big data tools such as radiomics and texture analysis in order to integrate all image parameters and different contrasts into individual tumor status. Then, accuracy, sensitivity and specificity will be evaluated by correlation of this data collection and analysis method with histological biomarkers (for example, Ki67 level) and treatment results.
Study: NCT00860717

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Description: The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.~Wound beds were irradiated using a scanning technique with no direct contact.
Study: NCT01141322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
Study: NCT03292315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide 1MG Injection [Ozempic]
Description: Once weekly injection of 1mg of Semaglutide.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No injection will be administered
Study: NCT01752465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coaching
Description: Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
Study: NCT02577198

Intervention type: OTHER
Group type: OTHER
Intervention: Medilogy Decision Support System (MediDSS)
Description: Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medilogy Decision Support System (MediDSS)
Description: Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
Study: NCT01277445

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic
Description: Inulin-fructan 15mg/day for 28days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotic
Description: Daily consumption of 15g inulin-fructan for 28 days
Study: NCT03777657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg IV on Day 1 during each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match tislelizumab on Day 1 during each 21-day cycle
Study: NCT01277445

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotic
Description: Daily consumption of 15g inulin-fructan for 28 days
Study: NCT02498769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
Study: NCT03776734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy application
Description: Effects of 5-10- 20 minutes cold application on quadriceps muscle
Study: NCT01164215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: 200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: 200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 85 mg/m2, intravenously for 2 hours, once every 2 weeks
Study: NCT00618033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodialysis
Description: varying concentration of glucose in dialysate
Study: NCT02498769

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03105934

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients with Pulmonary Arterial Hypertension
Description: 2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
Study: NCT01776567

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus eluting stents
Study: NCT05925244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Condition
Description: Control (no alteration to body mass).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: +12% Body Mass
Description: Loaded walking exercise (12% increase in body mass using a weighted vest).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: -12% Body Mass
Description: Unloaded walking exercise (12% decrease in body mass using lower body positive pressure).
Study: NCT04030663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: papaverine
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitroglycerine
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Study: NCT03777657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m² IV on Day 1 during each 21-day cycle
Study: NCT04030663

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: xlyocaine
Description: periradial injection of one of three drugs prior to cannulation of radial artery by 20 minutes and mesure the diamter of it by ultrasound
Study: NCT01253317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIGF-1
Description: 1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
Study: NCT01459263

Intervention type: DEVICE
Intervention: ClariVein
Description: Using the ClariVein device, the GSV will be occluded.
Study: NCT04598360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heart-Lung-Machine
Description: blood sample before and during a single Heart-Lung-Machine procedure
Study: NCT02915237

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concord grape juice
Description: Daily dietary supplementation with a commercially available Concord grape juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concord grape juice
Description: Daily dietary supplementation with a commercially available Concord grape juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Concord grape juice
Description: Daily dietary supplementation with a commercially available Concord grape juice.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
Study: NCT03166124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT00915837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
Study: NCT01367717

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Monohydrate
Description: Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Creatine Ethyl Ester
Description: Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
Study: NCT00982501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS® 1442 900 mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS® 1442 1800 mg/d

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nordic walking training 2 x 30 min/week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nordic walking training 4x45 min/week
Study: NCT03777657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m² IV on Day 1 during each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m² IV on Day 1 during each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m² IV on Day 1 during each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m² orally twice daily (BD) Days 1 through 14 (14 days total) during each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m²/day IV using continuous pumping system on Days 1 through 5 during each 21-day cycle
Study: NCT01839903

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EDIS
Description: Changes made to EDIS system to improve tracking and treatment of smoking in the ED

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Care as usual in the ED will be tracked

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care as usual
Description: Care as usual in the ED will be tracked
Study: NCT04537065

Intervention type: OTHER
Intervention: cycloplegic refraction
Description: Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).

Intervention type: OTHER
Intervention: cycloplegic refraction
Description: Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).

Intervention type: OTHER
Intervention: cycloplegic refraction
Description: Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).

Intervention type: OTHER
Intervention: cycloplegic refraction
Description: Cycloplegic refraction and the average corneal radius of curvature were performed using a handheld auto kerato-refractometer (Righton Retinomax K-plus2). Refraction was confirmed by retinoscopy and refractive errors were calculated as spherical equivalent and astigmatism in cylinder.~The biometric optic components, including anterior chamber depth, lens thickness, and axial length, were measured using A-scan ultrasound (model Echoscan US-4000 / 500; Nidek).
Study: NCT00822055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination
Description: 1 drop BID in each eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
Description: 1 drop BID in each eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
Description: 1 drop BID in each eye
Study: NCT02459899

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin,once daily, before the first meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin,once daily, before the first meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin,once daily, before the first meal of the day
Study: NCT03394027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625 mg by mouth every 7 days; each cycle = 28 days. Patients will receive ONC201 as long as they derive clinical benefit or toxicity becomes impeditive.
Study: NCT03310996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.